Background
==========

The 2009 H1N1 pandemic H1N1 influenza (flu) A (pdmH1N1) was first reported in Mexico and California \[[@B1]\]. As the virus spread globally, it became evident that the infection was of moderate severity with a broad clinical spectrum of symptoms \[[@B2]\]. Early data from Mexico suggested that pdmH1N1 may cause severe respiratory illness in otherwise healthy young and middle-aged people \[[@B3]\]. It is now estimated that in the United States pdmH1N1 caused higher rates of hospitalizations and deaths in children and adults 18--64 years of age than the flu of the previous season, but lower rates of clinical events in adults over 65 years of age \[[@B4]\]. This finding supports the notion that previous exposures to H1N1 in older individuals provides higher cross-protective immune responses than in younger individuals \[[@B5]\]. In the autumn of 2009, pdmH1N1 vaccines (pdm vaccines) were available across the globe, it was estimated that pdmH1N1 vaccination prevented 4,000--10,000 hospitalizations and 200--500 deaths in the US \[[@B6]\].

There are several unanswered questions concerning H1N1 flu infection and vaccination. Firstly, the impact of previous immune responses induced by flu vaccinations or by flu exposures on the ability to mount new anti-flu immune responses \[[@B7]-[@B9]\]. It is therefore of interest to map the adaptive humoral and cellular immune response prior to vaccination and prior to the onset of flu symptoms. Secondly, the differential quality and quantity of humoral and cellular immune responses directed against flu targets, induced either by flu vaccination or by flu infection, has not been well defined. Thirdly, several reports have discussed a 'silent infection' with H1N1 (in non-vaccinated participants), yet the real extent of such a silent infection is difficult to determine---in part due to cross-reacting antibodies (Abs) (from previous exposures or vaccines) \[[@B10]\]. Antibodies, as well as CD4+ and cytotoxic CD8+ T-cell immune responses, play a critical role in the host defense against flu \[[@B11],[@B12]\]. Increased cellular reactivity to flu, defined by IFN-γ production---a key cytokine in the pro-inflammatory response to flu---in participants who have not experienced influenza-like (ILI) symptoms, has not been determined up to now, this may help to identify silent flu infection.

In order to address these questions, we designed a prospective study of participants living in the Stockholm area in the context of the LifeGene (LG) project \[[@B13]\] to map in detail the breadth of the cellular immune responses *prior* to the onset of ILI symptoms and prior to vaccination with the pdm flu vaccine to study i) pre-existing immune responses, ii) the association of ILI symptoms with vaccination, iii) cellular immune reactivity during the flu season 2009--2010, directed against a broad panel of flu pathogens. This prospective study was designed to decipher differences in immune responses induced by infection with pdmH1N1 and the pdm vaccine, and this is the first report to describe in an unbiased fashion humoral and cellular immune responses during the pdmH1N1 infection in 2009--2010 in Sweden.

Methods
=======

Study participants
------------------

2,040 study participants from Stockholm (Sweden) entered the baseline step of the ILI study in September 2009, a part of the LG project \[[@B13]\]. For details see the Additional file [1](#S1){ref-type="supplementary-material"}: Text Material S1. Serum and heparin blood samples were drawn at study entry and after the flu season in the spring of 2010. Prepaid envelopes and nasal swabs were provided to participants after they had received instructions at the LifeGene study centres before study entry. Participants contacted the LG centres at the onset of ILI symptoms, filled out a questionnaire and mailed the (viral) swab for PCR analysis as described in detail in the supplementary data sets. If swabs tested positive for flu or coronavirus RNA, a home visit was payed during which an additional nasal swab and a blood sample from the index study participant and the household members was obtained. (The mean time between the first swab and the home visit was 2.5 weeks). The study was approved by the Ethics committee Stockholm south review board (DN 2009/1183-31) and each study participant provided informed consent. Swedish residents were offered the pdm vaccine Pandemrix (GSK) containing A/ H1N1/California/7/2009 (with AS03 adjuvant, i.e. DL-α-tocopherol, squalene and polysorbate).

Functional T-cell assay - whole-blood antigen stimulation assay
---------------------------------------------------------------

Forty μL of heparinised blood was diluted 1:5 in RPMI 1640 with L-glutamine (2 mM), penicillin (100 IU/mL) and streptomycin (10 mg/mL), and processed as described in detail in the supplementary data section (Additional file [1](#S1){ref-type="supplementary-material"}). The whole-blood antigen (WBA) stimulation assay measures the 'net' IFN-γ production elaborated by CD4+ and CD8+ T-cells in whole blood and reflects the activity of memory T-cell responses. We tested several flu antigens from previous monovalent flu vaccines, composed of haemagglutinin (HA) and neuraminidase (N) from flu A or B strains, for the capacity to elicit IFN-γ responses in T-cells: A/H1N1/Brisbane/59/2007, A/H1N1/Solomon Islands/3/2006, A/H3N2/Uruguay/716/2007, A/H3N2/Wisconsin/67/2005, B/Malaysia/2506/2004, B/Florida/4/2006, or A/H5N1/Vietnam/1203/2004, all provided by Baxter Innovations GmbH (Vienna, Austria). They were used at a final concentration of 2.5 μg/mL HA. We also tested the flu matrix antigens M1 and M2 present as peptides, and used at a final concentration of 1 μg/mL. As control, we used the CFP-10 antigen from *Mycobacterium tuberculosis*. We could not include the A/H1N1/California/7/2009 antigens in the cellular assays, since the test plates had to be prepared in advance due to quality control issues to ensure batch-to-batch consistency; the pdmH1N1 antigen preparation was not yet available in the summer of 2009 and the assay worked only with freshly obtained heparinised blood. In contrast to the cellular assay, Ab titres could be tested retrospectively.

Swab processing and PCR analysis
--------------------------------

If study participants experienced symptoms of ILI, they performed a nasal swab to be tested for 22 viral targets (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1) as described \[[@B14]\]. Swab processing and PCR are described in detail in the supplementary data section (Additional file [1](#S1){ref-type="supplementary-material"}: Text Material S1). This step was taken to link ILI symptoms with the detection of defined viral pathogens. In addition, if the PCR tested positive for H1N1, a nurse visited the participant 14 days (on average) after onset of symptoms in order to obtain a blood sample, which allowed study of the humoral and cellular immune response early after infection. This was also performed for participants infected with coronavirus as a control group.

Ab determination - single radial haemolysis test
------------------------------------------------

Sera, collected at study entry and after the flu season in the spring of 2010, and during a home visit in case of a positive H1N1 or coronavirus PCR (detected from a nasal swab), were stored at −80°C until testing. Single radial haemolysis (SRH) test against A/H1N1/California/07/2009 was performed at the Department of Physiopathology, Experimental Medicine and Public Health of the University of Siena according to procedures described in detail elsewhere \[[@B15]\]. Diameters of the haemolysis area for each serum tested were measured. Sera with areas of haemolysis equal to or higher than 4 mm^2^ but lower than 25 mm^2^ were considered to indicate seropositivity but not protection; haemolysis areas equal to or higher than 25 mm^2^ were considered to indicate seroprotection.

Statistical analysis
--------------------

Statistical analysis was performed on (i) the IFN-γ concentrations as a cellular response to flu and non-flu antigens, (ii) the PCR-based virus detection, (iii) the SRH Ab data, and (iv) the questionnaire data including symptoms reported in a web-based questionnaire by the study participants during and after the flu season. Data were analysed using SAS 9.2 software (SAS Institute). Descriptive statistics were used and Spearman analysis for independence was performed to verify integrity of data. Significance analysis was performed using the Pearson χ^2^-test, Student's t-test, and the Wilcoxon-Mann--Whitney two-sample rank-sum test. Multivariate operations, including operations on stratified variable dependencies and cluster analysis (using the VARCLUS procedure), were used in the analysis based on the combined dataset constituents, i.e. IFN-γ, PCR, antigen-specific Abs, symptoms, and vaccination. For each analysis, the nature of the statistical test used is indicated in the corresponding figure legend and table.

Results
=======

Study cohort
------------

After quality control (i.e. exclusion of samples without identification), the analysis group consisted of 1,971 participants: 1,807 adults aged between 18 and 65 years (median age 36, 53% women), 155 adults over 65 (median age 71 years, 65% women), and 9 children with a median age of 8 years. The baseline step (autumn/winter 2009) is designated time point 'A', and the event step (autumn/winter 2009) is designated time point 'B'. Altogether, 466 study participants mailed a swab for viral pathogen analysis and 618 participants filed a self-report (flu event questionnaire). For 41 study participants, a positive H1N1 or coronavirus PCR (for controls) triggered a home visit from a nurse to study the immune response at an early time point. The final step (spring 2010) is designated time point 'C', where 918 study participants (46.6% of the initial number of participants) again provided a blood sample (see overview of the study in Figure [1](#F1){ref-type="fig"}). This allowed us to study the humoral and cellular immune responses directed against flu---and also against control antigens---in an unbiased way.

![**Overview of the ILI study participants.** 1,971 study participants entered the study in the winter of 2009 (time point A); 67 samples were collected from study participants and household members during home visits triggered by an H1N1+ or coronavirus + PCR (detected in nasal swabs sent at time point B); 918 study participants returned for the follow-up sampling in the spring of 2010 (time point C).](1471-2334-14-319-1){#F1}

PdmH1N1 'swine flu' RNA could be detected in 27 swabs (24 from study participants and 3 from household members), and coronavirus RNA could be detected in 53 swabs (from 51 study participants and 2 household members) (see overview of the swabs analysis in Additional file [1](#S1){ref-type="supplementary-material"}: Table S2).

The initial set-point of A/H1N1/California/7/2009-specific antibodies and IFN-γ production
------------------------------------------------------------------------------------------

Study participants reported their flu vaccination status in the web questionnaires: 25.3% of study participants had received at least a single previous seasonal flu vaccination between 2006 and 2009; 63.1% (n = 755) of the study participants who responded to the follow-up questionnaire in the spring received the pdm flu vaccine in 2009--2010.

We evaluated the impact of previous flu vaccinations on IFN-γ production and A/H1N1/California/7/2009-specific Ab levels measured by SRH at study entry (Table [1](#T1){ref-type="table"}). The analysis showed significantly lower levels of IFN-γ production in response to A/H1N1/Brisbane/59/2007, A/H1N1/Solomon Islands/3/2006 and B/Florida/4/2006 in blood from study participants who had previously received seasonal flu vaccination (during the period 2006 to spring 2009) and who did not receive the pdm flu vaccine, than in those without any seasonal flu (or pdm) vaccination during the same period (p ≤ 0.04). We could not detect any significant differences in levels of A/H1N1/California/7/2009-specific Abs between vaccinated and unvaccinated participants. Notably, both groups were considered seropositive at SRH \> 4 mm^2^, but below protective levels (SRH \< 25 mm^2^), at time point A (Table [1](#T1){ref-type="table"}). Additionally, for time point A, we measured by the flu hemagglutination inhibition assay the presence of Abs directed against: A/H1N1/California/7/2009, A/H1N1/Brisbane/59/2007, A/H1N1/Solomon Islands/3/2006, A/H3N2/Uruguay/716/2007 and A/H5N1/Vietnam/1203/2004 in 7 participants (above 50 years of age) who had received previous seasonal flu vaccination, and 7 age-matched participants who had not received previous seasonal flu vaccination. Interestingly, 2 and 3 participants (out of 7 participants who did not receive seasonal flu vaccination) showed measurable levels of Abs specific for A/H1N1/Brisbane/59/2007 and A/H1N1/Solomon Islands/3/2006, respectively, but only 1 participant (out 7 participants who had received previous seasonal flu vaccination) showed measurable levels of Abs specific for A/H1N1/Solomon Islands/3/2006 (data not shown).

###### 

Mean values of A/H1N1/California/7/2009-specific Abs (measured by SRH) and IFN-γ production (in whole-blood assay) before (A) and after (C) the 2009--2010 flu season, in blood from study participants with our without seasonal flu vaccination (2006--2009)

      **Time point**                **A**                  **C**               **A**               **C**                     
  ----------------------- ------------------------- ------------------- ------------------- ------------------- ------------ -----------
   **A/H1N1/California**      18.3 (14.2--23.7)      19.6 (17.5--22.0)   19.1 (15.5--23.6)   21.2 (19.2--23.4)     *0.5*        *0.5*
                           **IFN-γ (pg/mL), mean**                                                                           
    **A/H1N1/Brisbane**              99                     144                 168                 172          ***0.04***     *0.6*
    **A/H1N1/Solomon**               85                     122                 152                 153          ***0.03***     *0.3*
    **A/H3N2/Uruguay**               137                    190                 221                 245            *0.12*       *0.3*
   **A/H3N2/Wisconsin**              162                    206                 226                 261            *0.3*        *0.2*
    **A/H5N1/Vietnam**               325                    361                 377                 373            *0.4*        *0.9*
       **B/Florida**                 204                    265                 260                 289          ***0.04***     *0.4*
      **B/Malaysia**                 154                    173                 164                 212            *0.14*       *0.2*
          **M1**                     24                     37                  35                  33             *0.14*      *0.14*
          **M2**                     18                     18                  19                  21             *0.7*        *0.7*
        **CFP-10**                   20                     22                  18                  23             *0.4*        *0.3*
          **PHA**                    518                    512                 545                 544            *0.6*        *0.5*
           **N**                     57                     175                 57                  175                            
    **Mean age, years**              50                     38                  50                  38           *\<0.001*    *\<0.001*

The Wilcoxon-Mann--Whitney rank-sum test was used to calculate p-values. ^1^V/NV: vaccinated vs. unvaccinated. Listed are Ab responses (top panel, directed against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a broad panel of flu targets (designated the flu A or flu B strains), and against matrix proteins M1 and M2. CFP10 served as a control. PHA was the positive control stimulus. P values below 0.05 are indicated in bold.

In contrast to the differences observed at entry into the study (time point A), no differences were observed in IFN-γ production between study participants with or without previous seasonal flu vaccinations (Table [1](#T1){ref-type="table"}) at time point C. At this time point, levels of A/H1N1/California/7/2009-specific Abs were below protective levels (SRH \< 25 mm^2^) in both vaccinated and unvaccinated participants.

The immunological footprint of pdm vaccination
----------------------------------------------

We followed the study participants who gave blood at time points A and C and reported (in the spring of 2010) their 2009--2010 pandemic vaccination status. At time point A, the levels of A/H1N1/California/7/2009-specific Abs and IFN-γ production in response to the flu antigens were comparable between participants who received (after time point A) the pdm flu vaccine and individuals who chose not to receive the vaccine (seropositive at SRH \> 4 mm^2^, but below protective levels (SRH \< 25 mm^2^)).

At time point C, the levels of A/H1N1/California/7/2009-specific Abs were above protective levels (SRH ≥ 25 mm^2^) in pdm flu vaccinated participants, the Ab levels were significantly higher (p \< 0.001) than in non-pmd flu vaccinated study participants. We also observed a statistically significant increase in IFN-γ production in response to all flu antigens (except for B/Malaysia/2506/2004), including the flu matrix antigen M1, in blood from study participants who received the pdm flu vaccine in the winter of 2009--2010 compared to the non-vaccinated study participants (p ≤ 0.04) (Table [2](#T2){ref-type="table"}; note that M1 is not a designated component of the flu vaccine).

###### 

Mean values of A/H1N1/California/7/2009-specific Abs (measured by SRH) and IFN-γ production in the whole-blood assay before (A) and after (C) the 2009/2010 flu season in study participants with our without pdm flu vaccination

  **Time point**                            **A**                          **C**               **A**               **C**                    
  ----------------------- ----------------------------------------- ------------------- ------------------- ------------------- ----------- ---------------
                           **SRH (mm**^**2**^**), geometric mean**                                                                          
  **A/H1N1/California**               20.1 (18.5--21.8)              19.3 (17.3--21.4)   27.9 (26.4--29.5)   20.7 (18.9--22.6)     *0.3*     ***\<0.001***
                                   **IFN-γ (pg/mL), mean**                                                                                  
  **A/H1N1/Brisbane**                        139                            133                 285                 169            *0.3*     ***\<0.001***
  **A/H1N1/Solomon**                         119                            113                 246                 151            *0.2*     ***\<0.001***
  **A/H3N2/Uruguay**                         194                            177                 304                 238            *0.2*     ***\<0.001***
  **A/H3N2/Wisconsin**                       203                            195                 301                 251            *0.6*     ***\<0.01***
  **A/H5N1/Vietnam**                         346                            352                 423                 373            *0.6*     ***\<0.01***
  **B/Florida**                              221                            250                 245                 283            *0.1*      ***0.04***
  **B/Malaysia**                             145                            168                 167                 200           *0.15*        *0.07*
  **M1**                                     33                             34                  63                  34             *0.8*     ***\<0.01***
  **M2**                                     18                             18                  20                  20             *0.4*         *0.8*
  **CFP-10**                                 21                             21                  24                  22             *0.7*         *0.2*
  **PHA**                                    501                            513                 506                 545           *0.13*        *0.02*
  **N**                                      437                            232                 437                 232                             
  **Mean age, years**                        47                             41                  47                  41           *\<0.001*     *\<0.001*

The Wilcoxon-Mann--Whitney rank-sum test was used to calculate p-values. ^1^V/NV: vaccinated vs. unvaccinated. Listed are Ab responses (top panel, directed against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a broad panel of flu targets (designated the flu A or flu B strains), and against matrix proteins M1 and M2. CFP10 served as control. PHA was the positive control stimulus. P values below 0.05 are indicated in bold.

Experience of ILI symptoms and the effect of pdm flu vaccination
----------------------------------------------------------------

We examined whether ILI symptoms segregated with the flu vaccination records. 58.0% of study participants who were vaccinated also reported the experience of ILI symptoms. 65 study participants who received the pdm flu vaccine and filed their ILI symptoms report later during the flu season (i.e. after December 2009, and after they had received the pdm flu vaccine) experienced significantly more symptoms than the 170 study participants who did not receive the pdm flu vaccine (and also reported their ILI symptoms after December 2009). Vaccinated study participants reported 4 ILI symptoms rather than 3 symptoms on average, i.e. nasal discharge (p = 0.02), fatigue (p = 0.04), cough (p = 0.01), sneezing (p = 0.04) and chills (p = 0.05) (Table [3](#T3){ref-type="table"}). The 45 study participants who received the pdm flu vaccine and mailed a swab later showed less frequent detection (6/45) of coronavirus RNA (p = 0.03), but showed a higher percentage (14/45) of rhinovirus RNA (p = 0.01) in their nasal swabs as compared to the 139 study participants who chose not to get vaccinated but mailed a swab due to symptoms of ILI (44/139).

###### 

Reported distribution of symptoms in study participants with or without pdm flu vaccination

  **Symptoms**                      **Vaccinated**   **Not vaccinated**   **Difference**         
  -------------------------------- ---------------- -------------------- ---------------- ------ ------------
  **Nasal discharge**                     43                15.1                84         14.8   ***0.02***
  **Fatigue**                             36                12.6                68         12.0   ***0.04***
  **Cough**                               35                12.3                61         10.7   ***0.01***
  **Headache**                            28                9.8                 62         10.9     *0.4*
  **Sneezing**                            35                12.3                66         11.6     *0.04*
  **Sore throat**                         23                8.1                 65         11.4     *0.7*
  **Muscle aches or joint pain**          26                9.1                 48         8.4      *0.08*
  **Chills**                              22                7.7                 36         6.3    ***0.05***
  **Other symptoms**                      9                 3.2                 20         3.5      *0.7*
  **Fever**                               9                 3.2                 20         3.5      *0.7*
  **Ear pain**                            7                 2.5                 21         3.7      *0.7*
  **Chest discomfort**                    6                 2.1                 9          1.6      *0.3*
  **Diarrhea**                            3                 1.1                 5          0.9      *0.5*
  **Itch**                                2                 0.7                 4          0.7      *0.8*
  **Vomiting**                            1                 0.4                 0          0.0      *0.1*
  **Symptoms N/%**                       285                100                569         100         
  **N**                                   65                 65                170         170         

Note the differential symptom presentation in participants vaccinated or not vaccinated against pdmH1N1. P values below 0.05 are indicated in bold.

IFN-γ production profiles and A/H1N1/California/7/2009-specific Abs showed differences in unvaccinated and vaccinated study participants depending on their ILI symptom status
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We analysed the immune status from study participants who did not report any symptoms of ILI since they were either (i) not exposed to pathogens leading to ILI symptoms, (ii) they may have been protected due to pre-existing anti-flu directed immune responses or pdm flu vaccination.

We show in Table [4](#T4){ref-type="table"} significant differences (time point C versus time point A) in IFN-γ production and A/H1N1/California/7/2009-specific Abs in blood samples from study participants who received the pdm flu vaccine and reported *no ILI symptoms* versus blood samples from unvaccinated study participants (reporting no ILI symptoms). At time point C (i.e. after the flu season) we identified higher levels of A/H1N1/California/7/2009-specific Abs (p \< 0.001) and IFN-γ production in response to A/H5N1/Vietnam/1203/2004 (p = 0.03), to A/H1N1/Brisbane/59/2007, to A/H1N1/Solomon Islands/3/2006 (p \< 0.001) as well as to the M1 matrix antigen (p \< 0.01) in study participants who received the pdm flu vaccine.

###### 

Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in study participants with or without pdmH1N1 vaccination who did not report any symptoms of ILI during the 2009--2010 flu season

                                     **Not vaccinated**              **Vaccinated**   **Difference**                            
  ----------------------- ----------------------------------------- ---------------- ---------------- ------ ------ ----- ----- ---------------
                           **SRH (mm**^**2**^**), geometric mean**                                                              
  **A/H1N1/California**                     20.9                          23.3             2.4         18.8   28.6   9.8   7.4   ***\<0.001***
                                   **IFN-γ (pg/mL), mean**                                                                      
  **A/H1N1/Brisbane**                        134                          164               30         101    234    134   105   ***\<0.01***
  **A/H1N1/ Solomon**                        117                          142               25          60    190    130   105   ***\<0.001***
  **A/H3N2/Uruguay**                         167                          232               64         148    256    109   37       *0.07*
  **A/H3N2/Wisconsin**                       172                          243               71         145    253    108   37        *0.4*
  **A/H5N1/Vietnam**                         338                          338               0          307    395    88    88     ***0.03***
  **B/Florida**                              233                          275               42         196    208    12    −27       *0.6*
  **B/Malaysia**                             155                          197               42         125    141    15    −27       *0.3*
  **M1**                                     32                            29               −3          22     49    27    30    ***\<0.01***
  **M2**                                     18                            22               4           18     18     0    −4        *0.9*
  **CFP-10**                                 19                            18               −1          20     23     3     4        *0.2*
  **PHA**                                    501                          538               37         517    519     2    −35       *0.8*
  **Mean IFN-γ diff.**                       163                          191               28         144    198    53    25           
  **N**                                      94                            94                          120    120                       

The Wilcoxon-Mann--Whitney rank-sum test was used to calculate the p-values (comparison of C-A between vaccinated and unvaccinated). ^1^V-N is vaccinated minus unvaccinated. Listed are Ab responses (top panel, directed against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a broad panel of flu targets (designated the flu A or flu B strains), and against matrix proteins M1 and M2. CFP10 served as control. PHA was the positive control stimulus. P values below 0.05 are indicated in bold.

Next, we examined IFN-γ production and A/H1N1/California/7/2009-specific Abs in blood from study participants (vaccinated and non-vaccinated) who reported ILI symptoms (Table [5](#T5){ref-type="table"}). We identified a slightly different immunological reactivity pattern as compared to the group of study participants who did not report any ILI symptoms at all (see above): (i) the increase (between time point C and time point A) in the mean value of A/H1N1/California/7/2009-specific Abs in unvaccinated and vaccinated study participants was not statistically significant, yet it reached protective levels (\>25 mm^2^) at time point C for pdm flu vaccinated study participants (ii) vaccinated study participants showed a significant increase in IFN-γ production in response to A/H1N1/Brisbane/59/2007 (p \< 0.001), to A/H3N2/Uruguay/716/2007, to A/H1N1/Solomon Islands/3/2006 (p ≤ 0.01), and to A/H3N2/Wisconsin/67/2005 (p = 0.02).

###### 

Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in study participants with or without pdmH1N1 vaccination who reported symptoms of ILI during the 2009--2010 flu season

                                     **Not vaccinated**              **Vaccinated**   **Difference**                            
  ----------------------- ----------------------------------------- ---------------- ---------------- ------ ------ ----- ----- ---------------
                           **SRH (mm**^**2**^**), geometric mean**                                                              
  **A/H1N1/California**                     15.3                          19.5             4.2         18.8   28.0   9.2   5.0       *0.1*
                                      **IFN-γ (pg/mL)**                                                                         
  **A/H1N1/Brisbane**                        169                          166               −2         113    296    183   185   ***\<0.001***
  **A/H1N1/Solomon**                         130                          180               50          80    262    182   132   ***\<0.01***
  **A/H3N2/Uruguay**                         197                          250               53         177    336    159   106    ***0.01***
  **A/H3N2/Wisconsin**                       217                          248               32         185    343    157   125    ***0.02***
  **A/H5N1/Vietnam**                         330                          374               44         310    403    93    49        *0.3*
  **B/Florida**                              254                          276               22         177    263    85    63        *0.4*
  **B/Malaysia**                             173                          203               30         108    208    101   71       *0.08*
  **M1**                                     43                            34              −10          31     62    31    41       *0.09*
  **M2**                                     18                            18               0           18     18     0     0        *0.3*
  **CFP-10**                                 18                            20               2           22     19    −3    −5        *0.7*
  **PHA**                                    505                          557               53         498    536    39    −14       *0.9*
  **Mean IFN-γ diff.**                       168                          200               33         146    230    84    51           
  **N**                                      49                            49                           47     47                       

The Wilcoxon-Mann--Whitney rank-sum test was used to calculate the p-values (comparison of C-A between vaccinated and unvaccinated). ^1^V-N is vaccinated minus unvaccinated. Listed are Ab responses (top panel, directed against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a broad panel of flu targets (designated the flu A or flu B strains), and against matrix proteins M1 and M2. CFP10 served as control. PHA was the positive control stimulus. P values below 0.05 are indicated in bold.

The immunological profile of H1N1 infection
-------------------------------------------

We analysed in greater detail the IFN-γ production and A/H1N1/California/7/2009-specific Abs from 21 study participants who tested positive for pdmH1N1 RNA and received a home visit (time point B) after the ILI symptom report (Table [6](#T6){ref-type="table"}); biological material from participants who tested positive for coronavirus RNA served as controls. Blood from participants with a positive pdmH1N1 PCR (but not the coronavirus positive controls), showed significantly higher levels of A/H1N1/California/7/2009-specific Abs (p ≤ 0.001) at time point B and at time point C (as compared to time point A, i.e. before the flu season). Participants testing positive for pdmH1N1 RNA also showed significantly higher levels of IFN-γ production at time point B than at time point A (p ≤ 0.01) in response to all flu antigens including M1, except for B/Florida/4/2006 and B/Malaysia/2506/2004.

###### 

Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in study participants who tested positive for H1N1 or coronavirus

                           **H1N1 positives**   **Corona positives**   **HC**^**B**^   **HC**^**C**^                                                                   
  ----------------------- -------------------- ---------------------- --------------- --------------- ------------- ------ ------ ------ ------ ------ --------------- -------------
    **A/H1N1/California**         16.1                  46.9               30.6        ***\<0.001***   ***0.003***   21.1   29.8   24.3   0.2    0.4    ***\<0.001***   ***0.001***
                           **IFN-γ (pg/mL)**                                                                                                                           
      **A/H1N1/Brisbane**          90                   460                 274        ***\<0.001***   ***0.01***    156    227    159    0.6    0.2    ***\<0.001***   ***0.01***
       **A/H1N1/Solomon**         104                   416                 272        ***\<0.001***   ***0.01***    124    212    159    0.2    0.2    ***\<0.01***    ***0.03***
       **A/H3N2/Uruguay**         125                   420                 292        ***\<0.001***     *0.09*      222    224    244    0.8    0.4    ***\<0.001***     *0.09*
     **A/H3N2/Wisconsin**         137                   408                 298        ***\<0.001***   ***0.02***    212    236    242    0.5    0.4     ***0.001***    ***0.04***
       **A/H5N1/Vietnam**         316                   546                 392        ***\<0.01***       *0.3*      355    394    367    0.7    0.8    ***\<0.01***       *0.3*
            **B/Florida**         218                   307                 327           *0.24*          *0.2*      216    370    240    0.08   0.7        *0.4*          *0.1*
           **B/Malaysia**         173                   260                 251           *0.06*         *0.25*      160    249    177    0.2    0.5        *0.7*         *0.11*
                   **M1**          34                   127                 48         ***\<0.01***      *0.08*       18     24     25    0.04   0.15      *0.07*         *0.25*
                   **M2**          19                    18                 19             *0.3*          *0.9*       18     18     18    0.9    0.9        *0.4*          *0.9*
               **CFP-10**          19                    25                 18             *0.9*          *0.3*       18     18     18    0.6    0.3        *0.9*          *0.7*
                  **PHA**         502                   535                 588            *0.9*         *0.08*      524    589    544    0.1    0.5        *0.2*         *0.25*
     **Mean IFN-γ diff.**         148                   265                 233                                      173    220    189                                        
                    **N**          21                    21                 21                                        38     15     38                                        

The Wilcoxon-Mann--Whitney rank-sum test was used to calculate the p-values. AB^1^: difference between time point A and B; AC^1^: difference between time point A and C; HC^B^: difference between pdmH1N1 positive and coronavirus positive at time point B. HC^C^ difference between pdmH1N1 positive and coronavirus positive at time point C. Note the strong immune responses at time point B in participants with pdmH1N1 infection; this response was reduced at the end of the study (time point C). P values below 0.05 are indicated in bold.

We observed significantly higher levels of IFN-γ production in response to only 3 flu antigens: A/H3N2/Wisconsin/67/2005, A/H1N1/Brisbane/59/2007 and A/H1N1/Solomon Islands/3/2006 in the flu season (time point C) as compared to the time point zero samples (timepoint A). Thus, the cellular immune response to the H1N1 infection was short-lived, it was directed against a broad panel of flu targets, defined by strong IFN-γ production and pronounced shortly after onset of symptoms (i.e. at the time of the home visit). This was not found to be true several months after the infection: the cellular immune response, defined by IFN-γ production, was weaker and directed only against a narrow panel of flu targets (time point C).

Next, we examined differences between IFN-γ production and A/H1N1/California/7/2009-specific Abs at time points A and C from (i) study participants who received the pdm flu vaccine and reported no ILI symptoms, and from study participants who did not receive the pdm flu vaccine and whose swab results did not test pdmH1N1 PCR positive and (ii) either reported at least one ILI or (iii) reported no ILI symptoms (Table [7](#T7){ref-type="table"}).

###### 

Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in blood from study participants with or without pdm flu vaccination and reported either symptoms or no symptoms of ILI

                                            **Vacc + & Sym+**              **Vacc + & Sym-**   **Vacc- & Sym+**   **Vacc- & Sym-**                                                              
  ----------------------------- ----------------------------------------- ------------------- ------------------ ------------------ ------ --------------- ------ ------ -------- ------ ------ --------------
                                 **SRH (mm**^**2**^**), geometric mean**                                                                                                                        
      **A/H1N1/California**                       20.6                           28.7           ***\<0.001***           20.4         28.2   **\<*0.001***   14.8   18.1   *0.4*    20.4   20.7      *0.9*
                                            **IFN-γ (pg/mL)**                                                                                                                                   
       **A/H1N1/Brisbane**                         126                            339           ***\<0.001***           115          279    ***\<0.001***   156    163    *0.2*    128    158     ***0.04***
   **A/H1N1/Solomon s/3/2006**                     97                             293           ***\<0.001***            90          231    ***\<0.001***   121    164    *0.2*    108    140    ***0.001***
       **A/H3N2/Uruguay**                          195                            350           ***\<0.001***           162          297    ***\<0.001***   224    256    *0.3*    170    233    ***\<0.01***
      **A/H3N2/Wisconsin**                         207                            346           ***\<0.001***           170          294    ***\<0.001***   247    264    *0.4*    200    245     ***0.04***
       **A/H5N1/Vietnam**                          346                            426             ***0.03***            325          427    ***\<0.001***   336    382    *0.3*    347    363       *0.7*
          **B/Florida**                            231                            316             ***0.04***            202          230       *0.06*       280    286    *0.8*    230    267       *0.09*
         **B/Malaysia**                            138                            204             ***0.03***            129          163    ***\<0.01***    191    221    *0.4*    157    183       *0.1*
             **M1**                                31                             81             ***\<0.01***            27           51    ***\<0.001***    37     26    *0.3*     30     36       *0.5*
             **M2**                                18                             18                *0.3*                18           20     ***0.03***      18     18    *0.3*     18     20       *0.5*
           **CFP-10**                              21                             19                *0.3*                22           24        *0.4*        18     18    *0.9*     21     22       *0.5*
             **PHA**                               513                            521               *0.3*               495          513       *0.05*       500    546    *0.15*   516    534       *0.3*
         **Mean IFN-γ**                            165                            240                                   151          211                    173    199             164    192          
              **N**                                69                             69                                    312          312                     48     48             208    208          

The Wilcoxon-Mann--Whitney rank-sum test was used to calculate the p-values (difference between time point A and B). Note the increased antigen-specific cellular immune responses in blood from participants who did not receive the vaccine and did not report any ILI symptoms. P values below 0.05 are indicated in bold.

We observed significantly increased levels (between time points A and C; p ≤ 0.003) of A/H1N1/California/7/2009-specific Abs in blood from participants who tested positive for H1N1 (and did not receive pdm vaccination; mean increase in Ab titre (SRH): 14.5), and from study participants who received the pdm vaccine (mean increase in Ab titre (SRH): 8). A/H1N1/California/7/2009-specific Abs were above protective levels (\>25 mm^2^) for those both groups (vaccinated or non-vaccinated) at time point C.

No significant difference between time points A and C (before and after the flu season) concerning A/H1N1/California/7/2009-specific antibody levels was observed in the group of participants who either tested negative for H1N1 or received flu vaccination (regardless of the reported ILI symptom status); both groups were seropositive but exhibited antibody titres below protective levels.

We observed a very similar IFN-γ production profile in blood from participants who (i) did not receive the pdm flu vaccination, (ii) tested negative for pdmH1N1 and (iii) reported *no* ILI symptoms compared to those who tested H1N1 positive: increased IFN-γ production in response to the flu antigens A/H1N1/Brisbane/59/2007, A/H1N1/Solomon Islands/3/2006, A/H3N2/Wisconsin/67/2005 and A/H3N2/Uruguay/716/2007 (p ≤ 0.04).

Discussion
==========

This study showed that pdm flu vaccination (A/California/7/2009) induced increased levels of A/H1N1/California/7/2009-specific Abs, but also strong immune cellular responses (measured by IFN-γ production in a whole-blood assay) directed against flu A antigens from H1N1, H3N2 and H5N1 strains, flu B strains, and the flu M1 matrix antigen.

We have not been able to include the pdm flu strain. However, increased IFN-γ production after vaccination suggested that A/California/7/2009-specific T-cell responses were induced by pdm flu vaccination. This would imply that pdm flu vaccine induced (cross)-reactive cellular responses did not only target the flu A H1N1 strains, but also H3N2, H5N1 and flu B strains. In agreement with this observation, we showed that participants who received the pdm flu vaccination exhibited also a significant increase in Ab titers directed against A/H1N1/Solomon Islands/3/2006 and A/H5N1/Vietnam/1203/2004, while participants who did not receive the pdm flu vaccine exhibited only a significant increase in A/H1N1/California/7/2009-specific Abs but not in Abs against the other flu A strains tested by the flu hemagglutination inhibition assay (data not shown).

The flu vaccine, studied in this report, represents a split virus vaccine, which is mainly composed of surface membrane glycoproteins, yet traces of M1 have also been detected \[[@B16]\] as part of the vaccine formulation. We tested M1 and M2 as targets for cellular immune responses in the current study. The M2 protein is a proton-selective ion channel protein, integral in the viral envelope of the influenza A virus. M2 brings protons into the virion core. Acidification of virus interior, leads to weakening of electrostatic interaction and leads to dissociation between M1 (matrix protein) and viral rib nucleoprotein (RNP) complexes \[[@B17]\]. Traces of M1 in the split vaccine may be responsible for the strong anti-M1 directed responses defined by IFN-γ production, which has not been reported until now. Flu vaccines are produced and standardised based on their haemagglutinin and neuraminidase content, and traces of the M1 proteins, contained in the current standard vaccines, may in part be responsible for conferring protective immune responses between flu A strains, since the M1 protein is quite conserved \[[@B18]\]. The M1-directed cellular immune responses, along with traces of M1 proteins in split vaccines may in part responsible for the cross-reactive immune responses against H5N1 associated with the pdm flu vaccine, since CD4+ and CD8+ T-cell responses directed against H5N1 have preferentially reported to focus on M1 or NP (nucleoproteins) \[[@B19]\].

In addition, we showed at study entry that previous seasonal flu vaccination (in 2006--2009) did not lead to an increased IFN-γ production in response to flu antigen components from 2006--2009 flu vaccines, but was instead associated with significantly *lower* IFN-γ production in response to flu antigen components from 2008--2009 flu vaccines (A/H1N1/Brisbane/59/2007, A/H1N1/Solomon Islands/3/2006 and B/Florida/4/2006). A similar trend was observed when analysing H1N1/Brisbane/59/2007- and A/H1N1/Solomon Islands/3/2006-specific antibodies. However, at the end of the study, we could not detect significant differences in IFN-γ production in response to flu antigens between previously vaccinated and unvaccinated participants. This suggests that after the flu season, previously vaccinated and unvaccinated participants were able to mount comparable immune responses (as measured by IFN-γ production in the whole-blood assay).

A recent report showed that individuals with a history of seasonal flu vaccination exhibited after natural pdm flu infection or pdm flu vaccination a skewed Ab response towards previously encountered flu antigens, further proving the impact of previous flu vaccination on subsequent infection or vaccination \[[@B20]\]. Seasonal flu vaccination of children has been reported to interfere with the development of heterosubtypic immunity \[[@B21]\] and Ab responses to pandemic H1N1 appeared to be reduced in participants who received seasonal flu vaccination 3 months prior to vaccination with the pmd flu vaccine \[[@B22]\]. The report by Skowronski and co-workers also suggested an association between the previous 2008--2009 flu vaccination and pandemic H1N1 illness in Canada \[[@B23]\]; the mechanisms underlying this finding are ill-defined and warrant further research to better understand the impact of seasonal flu vaccination, i.e. the potential 'negative imprint' of previous vaccinations on cellular immune memory responses.

Reservations about flu vaccination, including the notion that flu vaccination would not result in appropriate protection, have been discussed in the public domain \[[@B24]-[@B26]\]. One of the arguments is that flu vaccination may not protect against ILI *symptoms* during flu the season. This notion was corroborated in our study. A number of study participants, after pdm flu vaccination, experienced more ILI symptoms, perhaps due to the observed increase in prevalence of rhinovirus infection in pdm flu vaccinated participants as compared to non-pdm flu vaccinated participants. Other reasons may account for these observations, one of them being the low predictive value of the ILI case definition \[[@B26]\]. Future prospective studies may address the question whether certain flu vaccines are able to increase cellular immune responses in the respiratory system, particularly after encounter with the wildtype flu. Increased 'influenza-like' symptoms may occur upon exposure to additional pathogens, such as rhino- or coronavirus, that stimulate 'flu-primed' innate or adaptive immune responses. This hypothesis is supported by the observation that infection with rhinovirus may have delayed the circulation of H1N1, most likely via activation of non-specific innate immune responses in the respiratory system \[[@B27]\].

Study participants who received the pdm flu vaccine showed similar IFN-γ production profiles in response to the flu antigens tested, irrespective of the experience of ILI symptoms. However, we observed that study participants who received the pdm flu vaccine and reported ILI symptoms (compared to non-pdm flu vaccinated participants with ILI symptoms), showed by the end of the study a comparable increase in A/California/7/2009-specific Abs and an increase in IFN-γ production in response to the flu A H1N1 and H3N2 strains. This immune status could not be observed in participants who reported no ILI symptoms, irrespective of whether or not they received the pmd flu vaccination. This suggests that some pmd flu vaccinated participants who reported ILI symptoms may have been exposed to the H3N2 seasonal flu supporting previous observations that pmd flu vaccination did not affect the rate of H3N2 infections \[[@B28]\]. The pdmH1N1 strain dominated the flu season in Sweden in 2009--2010, but flu H3N2 and flu B were also present in 1.7% and 1.4% of the samples analysed by the Swedish National Influenza Centre \[[@B29]\].

The comparable increase in A/H1N1/California/7/2009-specific Abs in serum from unvaccinated and pdm flu vaccinated study participants who reported ILI symptoms also suggests that non-pdm flu vaccinated study participants may have been exposed to the pdm flu.

We speculate that the non-pdm flu vaccinated study participants who reported ILI symptoms had been exposed to the pdm flu. These individuals exhibited lower levels of IFN-γ production in response to the H1N1 and H3N2 flu antigens as compared to *pmd flu vaccinated* study participants who reported ILI symptoms. This would also fit with the hypothesis that IFN-γ production directed against related flu antigens upon natural by pdmH1N1 infection is short-lived as compared to IFN-γ induced by pdm flu vaccination. This notion was indeed corroborated: we showed that shortly after a positive pdmH1N1 PCR, IFN-γ production to most of the flu antigens was significantly increased, yet declined by the end of the study (May 2010). In contrast, we could detect significantly higher levels of IFN-γ production in response to M1 (which is not a designated vaccine component) at the end of the study in pdm flu vaccinated participants; this was not the case for study participants who tested positive for pdmH1N1 by PCR (Table [6](#T6){ref-type="table"}).

Finally, our observation that study participants i) with a negative pdm flu PCR ii) absent pdm flu vaccination and iii) a negative ILI symptom report, showed increased IFN-γ production in response to most of the flu antigens, concomitant with the absence of A/H1N1/California/7/2009-specific Ab increase, suggests that these individuals may have been exposed to pdm flu, i.e. that they were 'silently infected' and developed a strong anti-pdm flu T-cell (but not a B-cell) response.

Conclusions
===========

The detection of stronger cellular responses measured after the flu season, directed against M1, from study participants who received pdm flu vaccination (as compared to study participants who had a natural pdm flu infection) argues for a more detailed analysis of the role of M1-specific cellular responses induced by vaccination. M1 responses are currently discussed to be crucial in mediating protective anti-flu directed immune responses \[[@B30]\] and may therefore become an important component of future vaccines. The prospective study layout of the LifeGene ILI cohort also demonstrates the value of a time point zero sample to gauge the immune response prior to a vaccination or exposure: pre-existing humoral and cellular immune responses shape the nature of the immune response associated with immune protection or immune pathology.
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